Biotechnology News and Research

RSS

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received a new patent in the United States.

30 Apr 2010

United Therapeutics reports strong revenue growth in first quarter 2010

United Therapeutics Corporation today announced its results of operations for the quarter ended March 31, 2010.

30 Apr 2010

Mylan first-quarter total revenues increase 7% to $1.29 billion

Mylan Inc. today announced its financial results for the three months ended March 31, 2010.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

SickKids receives $8.9M grant for autism research

A research team co-led by Dr. Stephen Scherer, Senior Scientist at The Hospital for Sick Children (SickKids) was awarded an $8.9 million grant today from the Global Leadership Round in Genomics & Life Sciences (GL(2)), which is part of the Ontario Research Fund (ORF) by the Ministry of Research and Innovation (MRI).

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. has received disciplinary notice from China's State Food and Drug Administration regarding its production of substandard quality human use rabies vaccine.

29 Apr 2010

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application for sirolimus tablets in the 1 mg and 2 mg strengths.

29 Apr 2010

New EDUCARE project to train healthcare workers combat cancer epidemic in Africa

Roche announced today the launch of the EDUCARE project, which, in concert with IAEA, will provide support to help combat the growing cancer epidemic in sub-Saharan Africa.

29 Apr 2010

ECRI Institute's recommendations for controlling CT radiation dose

The benefits of computed tomography (CT) have increased greatly over the past decade. Now twice as powerful, it offers dynamic images of anatomy, including the beating heart. Future advancements promise to deliver even more clinical benefits. However, CT has always had a downside: it can deliver high radiation doses to patients, putting them at increased risk of developing cancer.

29 Apr 2010

Biotechnology News and Research

PROVENGE receives FDA approval for treatment of CRPC

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

United Therapeutics reports strong revenue growth in first quarter 2010

Mylan first-quarter total revenues increase 7% to $1.29 billion

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Immunogen reports a net loss of $12.1 million in third quarter 2010

UC Irvine scientists receive CIRM grants for stem cell research

SickKids receives $8.9M grant for autism research

FDA approves Provenge prostate cancer vaccine

BioTime to acquire Singapore-based company, ES Cell International

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

New EDUCARE project to train healthcare workers combat cancer epidemic in Africa

ECRI Institute's recommendations for controlling CT radiation dose

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News